Is it really myositis? Mimics and pitfalls

McHugh, 2018, Autoantibodies in myositis, Nat Rev Rheumatol, 14, 290, 10.1038/nrrheum.2018.56 Betteridge, 2016, Myositis-specific autoantibodies: an important tool to support diagnosis of myositis, J Intern Med, 280, 8, 10.1111/joim.12451 Tansley, 2017, Autoantibodies in juvenile-onset myositis: their diagnostic value and associated clinical phenotype in a large UK cohort, J Autoimmun, 84, 55, 10.1016/j.jaut.2017.06.007 Betteridge, 2019, Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients, J Autoimmun, 101, 48, 10.1016/j.jaut.2019.04.001 Bronner, 2006, Long-term outcome in polymyositis and dermatomyositis, Ann Rheum Dis, 65, 1456, 10.1136/ard.2005.045690 Lundberg, 2021, Idiopathic inflammatory myopathies, Nat Rev Dis Prim, 7, 86, 10.1038/s41572-021-00321-x Bohan, 1975, Polymyositis and dermatomyositis: (first of two parts), N Engl J Med, 292, 344, 10.1056/NEJM197502132920706 Bohan, 1975, Polymyositis and dermatomyositis: (second of two parts), N Engl J Med, 292, 403, 10.1056/NEJM197502202920807 Lundberg, 2017, 2017 European League against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups, Ann Rheum Dis, 76, 1955, 10.1136/annrheumdis-2017-211468 Baig, 2020, Inflammatory muscle disease – an update, Best Pract Res Clin Rheumatol, 34, 10.1016/j.berh.2019.101484 Oldroyd, 2018, Recent developments in classification criteria and diagnosis guidelines for idiopathic inflammatory myopathies, Curr Opin Rheumatol, 30, 606, 10.1097/BOR.0000000000000549 Schmidt, 2018, Current classification and management of inflammatory myopathies, J Neuromuscul Dis, 5, 109, 10.3233/JND-180308 Selva-O’Callaghan, 2018, Classification and management of adult inflammatory myopathies, Lancet Neurol, 17, 816, 10.1016/S1474-4422(18)30254-0 Lundberg, 2018, Classification of myositis, Nat Rev Rheumatol, 14, 269, 10.1038/nrrheum.2018.41 Allenbach, 2017, Integrated classification of inflammatory myopathies, Neuropathol Appl Neurobiol, 43, 62, 10.1111/nan.12380 Mammen, 2020, 239th ENMC international workshop: classification of dermatomyositis, amsterdam, The Netherlands, 14–16 december 2018, Neuromuscul Disord, 30, 70, 10.1016/j.nmd.2019.10.005 Suárez-Calvet, 2017, RIG-I expression in perifascicular myofibers is a reliable biomarker of dermatomyositis, Arthritis Res Ther, 19, 174, 10.1186/s13075-017-1383-0 Pinal-Fernandez, 2015, The prevalence of individual histopathologic features varies according to autoantibody status in muscle biopsies from patients with dermatomyositis, J Rheumatol, 42, 1448, 10.3899/jrheum.141443 Uruha, 2019, Diagnostic potential of sarcoplasmic myxovirus resistance protein A expression in subsets of dermatomyositis, Neuropathol Appl Neurobiol, 45, 513, 10.1111/nan.12519 Hervier, 2013, Clinical heterogeneity and outcomes of antisynthetase syndrome, Curr Rheumatol Rep, 15, 349, 10.1007/s11926-013-0349-8 Opinc, 2021, Antisynthetase syndrome – much more than just a myopathy, Semin Arthritis Rheum, 51, 72, 10.1016/j.semarthrit.2020.09.020 Trallero-Araguás, 2019, Influence of antisynthetase antibodies specificities on antisynthetase syndrome clinical spectrum time course, J Clin Med, 8, 2013, 10.3390/jcm8112013 Noguchi, 2017, Skeletal muscle involvement in antisynthetase syndrome, JAMA Neurol, 74, 992, 10.1001/jamaneurol.2017.0934 Mescam-Mancini, 2015, Anti-Jo-1 antibody-positive patients show a characteristic necrotizing perifascicular myositis, Brain, 138, 2485, 10.1093/brain/awv192 Mammen, 2012, Increased frequency of DRB1∗11:01 in anti-HMG-CoA reductase-associated autoimmune myopathy, Arthritis Care Res, 10.1002/acr.21671 Christopher-Stine, 2010, A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy, Arthritis Rheum, 62, 2757, 10.1002/art.27572 Lim, 2019, Seronegative patients form a distinctive subgroup of immune-mediated necrotizing myopathy, Neurol Neuroimmunol Neuroinflammation, 6, e513, 10.1212/NXI.0000000000000513 Allenbach, 2016, High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody, Brain, 139, 2131, 10.1093/brain/aww054 Naddaf, 2018, Inclusion body myositis: update on pathogenesis and treatment, Neurotherapeutics, 15, 995, 10.1007/s13311-018-0658-8 Greenberg, 2019, Inclusion body myositis: clinical features and pathogenesis, Nat Rev Rheumatol, 15, 257, 10.1038/s41584-019-0186-x Cox, 2009, Detecting dysphagia in inclusion body myositis, J Neurol, 256, 2009, 10.1007/s00415-009-5229-9 Ø, 2016, Epidemiology of sporadic inclusion body myositis, Curr Opin Rheumatol, 28, 657, 10.1097/BOR.0000000000000327 Lloyd, 2016, Cytosolic 5′-nucleotidase 1A as a target of circulating autoantibodies in autoimmune diseases: circulating autoantibodies against cytosolic 5′-nt1a, Arthritis Care Res, 68, 66, 10.1002/acr.22600 Herbert, 2016, Disease specificity of autoantibodies to cytosolic 5′-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases, Ann Rheum Dis, 75, 696, 10.1136/annrheumdis-2014-206691 Lloyd, 2017, Overlapping features of polymyositis and inclusion body myositis in HIV-infected patients, Neurology, 88, 1454, 10.1212/WNL.0000000000003821 Cupler, 1996, Inclusion body myositis in HIV-1 and HTLV-1 infected patients, Brain, 119, 1887, 10.1093/brain/119.6.1887 Sanmaneechai, 2015, Inclusion body myositis and sarcoid myopathy: coincidental occurrence or associated diseases, Neuromuscul Disord, 25, 297, 10.1016/j.nmd.2014.12.005 Uruha, 2016, Hepatitis C virus infection in inclusion body myositis: a case-control study, Neurology, 86, 211, 10.1212/WNL.0000000000002291 Ikenaga, 2017, Clinicopathologic features of myositis patients with CD8-MHC-1 complex pathology, Neurology, 89, 1060, 10.1212/WNL.0000000000004333 Dalakas, 2002, Muscle biopsy findings in inflammatory myopathies, Rheum Dis Clin N Am, 28, 779, 10.1016/S0889-857X(02)00030-3 Dubourg, 2011, Diagnostic value of markers of muscle degeneration in sporadic inclusion body myositis, Acta Myol Myopathies Cardiomyopathies Off J Mediterr Soc Myol, 30, 103 Muro, 2017, Prevalence of anti-NT5C1A antibodies in Japanese patients with autoimmune rheumatic diseases in comparison with other patient cohorts, Clin Chim Acta, 472, 1, 10.1016/j.cca.2017.07.002 van der Meulen, 2003, Polymyositis: an overdiagnosed entity, Neurology, 61, 316, 10.1212/WNL.61.3.316 Vilela, 2015, Polymyositis, a very uncommon isolated disease: clinical and histological re-evaluation after long-term follow-up, Rheumatol Int, 35, 915, 10.1007/s00296-014-3198-5 Oldroyd, 2021, A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies, Rheumatology, 60, 2615, 10.1093/rheumatology/keab166 Yang, 2017, Identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study, Arthritis Res Ther, 19, 259, 10.1186/s13075-017-1469-8 Maliha, 2019, 18F-FDG PET/CT versus conventional investigations for cancer screening in autoimmune inflammatory myopathy in the era of novel myopathy classifications, Nucl Med Commun, 40, 377, 10.1097/MNM.0000000000000981 Selva-O’Callaghan, 2010, Conventional cancer screening versus PET/CT in dermatomyositis/polymyositis, Am J Med, 123, 558, 10.1016/j.amjmed.2009.11.012 Ilzecka, 2003, Creatine kinase activity in amyotrophic lateral sclerosis patients, Neurol Sci, 24, 286, 10.1007/s10072-003-0158-3 Katiriji, 2001, Creatine kinase revisited, J Clin Neuromuscul Dis, 2, 158, 10.1097/00131402-200103000-00008 Park, 2013, Pulmonary impairment, not muscle injury, is associated with elevated ESR in the idiopathic inflammatory myopathies, Rheumatology, 52, 1336, 10.1093/rheumatology/ket162 Martinez-Thompson, 2021, Electrodiagnostic assessment of myopathy, Neurol Clin, 39, 1035, 10.1016/j.ncl.2021.06.007 Sener, 2019, Needle electromyography and histopathologic correlation in myopathies, Muscle Nerve, 59, 315, 10.1002/mus.26381 Lovitt, 2004, MRI in myopathy, Neurol Clin, 22, 509, 10.1016/j.ncl.2004.03.008 Mercuri, 2007, Muscle MRI in inherited neuromuscular disorders: past, present, and future, J Magn Reson Imag, 25, 433, 10.1002/jmri.20804 Nix, 2020, What every neuropathologist needs to know: the muscle biopsy, J Neuropathol Exp Neurol, 79, 719, 10.1093/jnen/nlaa046 Dorph, 2001, Percutaneous conchotome muscle biopsy. A useful diagnostic and assessment tool, J Rheumatol, 28, 1591 Statland, 2016, Facioscapulohumeral muscular dystrophy, Contin Lifelong Learn Neurol, 22, 1916, 10.1212/CON.0000000000000399 Lundberg, 1995, Analysis of cytokine expression in muscle in inflammatory myopathies, Duchenne dystrophy, and non-weak controls, J Neuroimmunol, 63, 9, 10.1016/0165-5728(95)00122-0 Fanin, 2002, Muscle pathology in dysferlin deficiency, Neuropathol Appl Neurobiol, 28, 461, 10.1046/j.1365-2990.2002.00417.x Jain, 2007, Major histocompatibility complex class I and II detection as a diagnostic tool in idiopathic inflammatory myopathies, Arch Pathol Lab Med, 131, 1070, 10.5858/2007-131-1070-MHCCIA van der Pas, 2004, Diagnostic value of MHC class I staining in idiopathic inflammatory myopathies, J Neurol Neurosurg Psychiatry, 75, 136 Rodríguez Cruz, 2014, An analysis of the sensitivity and specificity of MHC-I and MHC-II immunohistochemical staining in muscle biopsies for the diagnosis of inflammatory myopathies, Neuromuscul Disord, 24, 1025, 10.1016/j.nmd.2014.06.436 Mamyrova, 2013, Clinical and laboratory features distinguishing juvenile polymyositis and muscular dystrophy: features distinguishing juvenile polymyositis and dystrophies, Arthritis Care Res, 65, 1969, 10.1002/acr.22088 Brandsema, 2015, Dystrophinopathies. Semin Neurol., 35, 369, 10.1055/s-0035-1558982 Falzarano, 2015, Duchenne muscular dystrophy: from diagnosis to therapy, Molecules, 20, 18168, 10.3390/molecules201018168 Seguí, 2020, Anoctamin 5 (ANO5) muscular dystrophy—three different phenotypes and a new histological pattern, Neurol Sci, 41, 2967, 10.1007/s10072-020-04453-y Arahata, 1995, Inflammatory response in facioscapulohumeral muscular dystrophy (FSHD): immunocytochemical and genetic analyses, Muscle Nerve, 18, S56, 10.1002/mus.880181312 Duyff, 2000, Neuromuscular findings in thyroid dysfunction: a prospective clinical and electrodiagnostic study, J Neurol Neurosurg Psychiatry, 68, 750, 10.1136/jnnp.68.6.750 Anwar, 2010, Musculoskeletal manifestations of thyroid disease, Rheum Dis Clin N Am, 36, 637, 10.1016/j.rdc.2010.09.001 Tiniakou, 2015, Necrotizing myopathy caused by central hypothyroidism, Muscle Nerve, 52, 152, 10.1002/mus.24637 Puvanendran, 1979, Neuromuscular transmission in thyrotoxicosis, J Neurol Sci, 43, 47, 10.1016/0022-510X(79)90072-8 Smith, 1969, Muscular weakness in osteomalacia and hyperparathyroidism, J Neurol Sci, 8, 511, 10.1016/0022-510X(69)90010-0 Patten, 1974, Neuromuscular disease in primary hyperparathyroidism, Ann Intern Med, 80, 182, 10.7326/0003-4819-80-2-182 Pasnoor, 2018, Toxic myopathies, Curr Opin Neurol, 31, 575, 10.1097/WCO.0000000000000606 Mammen, 2013, Toxic Myopathies: Contin Lifelong Learn Neurol, 19, 1634 Mohassel, 2013, The spectrum of statin myopathy, Curr Opin Rheumatol, 25, 747, 10.1097/01.bor.0000434673.85515.89 Litin, 1989, Nicotinic acid-associated myopathy: a report of three cases, Am J Med, 86, 481, 10.1016/0002-9343(89)90352-5 Fux, 2004, Ezetimibe and statin-associated myopathy, Ann Intern Med, 140, 671, 10.7326/0003-4819-140-8-200404200-00034 Havranek, 2006, Monotherapy with ezetimibe causing myopathy, Am J Med, 119, 285, 10.1016/j.amjmed.2005.06.051 London, 1991, Cholesterol-lowering agent myopathy (CLAM), Neurology, 41, 1159, 10.1212/WNL.41.7.1159 Gupta, 2013, Glucocorticoid-induced myopathy: pathophysiology, diagnosis, and treatment, Indian J Endocrinol Metab, 17, 913, 10.4103/2230-8210.117215 Argov, 1988, Drug-induced neuromuscular disorders Amato, 2016, Toxic myopathies, 737 Kostine, 2019, Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy, Rheumatology, 58, 10.1093/rheumatology/kez295 Suzuki, 2017, Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan, Neurology, 89, 1127, 10.1212/WNL.0000000000004359 Tarnopolsky, 2016, Metabolic myopathies, Contin Lifelong Learn Neurol, 22, 1829, 10.1212/CON.0000000000000403 Bhai, 2021 Haller, 2002, Spontaneous “second wind” and glucose-induced second “second wind” in McArdle disease: oxidative mechanisms, Arch Neurol, 59, 1395, 10.1001/archneur.59.9.1395 Hogrel, 2001, A non-ischemic forearm exercise test for the screening of patients with exercise intolerance, Neurology, 56, 1733, 10.1212/WNL.56.12.1733 Taivassalo, 2003, The spectrum of exercise tolerance in mitochondrial myopathies: a study of 40 patients, Brain, 126, 413, 10.1093/brain/awg028 Machado, 2014, Sporadic inclusion body myositis: new insights and potential therapy, Curr Opin Neurol, 27, 591, 10.1097/WCO.0000000000000129 Nicolau, 2020, Myopathies with finger flexor weakness: not only inclusion-body myositis, Muscle Nerve, 62, 445, 10.1002/mus.26914 Bouchard, 2015, Natural history of skeletal muscle involvement in myotonic dystrophy type 1: a retrospective study in 204 cases, J Neurol, 262, 285, 10.1007/s00415-014-7570-x Dieudonné, 2020, Granulomatosis-associated myositis: high prevalence of sporadic inclusion body myositis, Neurology, 94, e910, 10.1212/WNL.0000000000008863 Heim, 2020, Amyloid myopathy as an inclusion body myositis mimic, RRNMF Neuromuscul J, 1, 28, 10.17161/rrnmf.v1i4.13699 Smestad, 2004, Amyloid myopathy presenting with distal atrophic weakness, Muscle Nerve, 29, 605, 10.1002/mus.10528 De Bleecker, 2015, 205th ENMC international workshop: pathology diagnosis of idiopathic inflammatory myopathies Part II 28–30 march 2014, naarden, The Netherlands, Neuromuscul Disord, 25, 268, 10.1016/j.nmd.2014.12.001 Olivier, 2019, Idiopathic inflammatory myopathy: interrater variability in muscle biopsy reading, Neurology, 93, e889, 10.1212/WNL.0000000000008005 van de Vlekkert, 2014, Long-term follow-up of 62 patients with myositis, J Neurol, 261, 992, 10.1007/s00415-014-7313-z